- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | - / - |
| Spread | - |
| Schluss Vortag | - |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief - Tageshoch - | |
| 52W-Tief - 52W-Hoch 0,801 | |
| Jahrestief - Jahreshoch 0,70 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 03.02.26 | 0,6036 | 8.217 |
| 30.01.26 | 0,57 | 8.908 |
| 29.01.26 | 0,555 | 20.121 |
| 28.01.26 | 0,6365 | 20.113 |
| 27.01.26 | 0,482 | 121 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | - | - |
| 1 Monat | - | - |
| 6 Monate | 0,051 | - |
| 1 Jahr | 0,03 | - |
| 5 Jahre | - | - |
| Marktkapitalisierung | 1,85 Mio. € |
| Aktienanzahl | 42,59 Mio. |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
Merger mit Biosight
-Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
-Combined Company Will be Well-Funded with Cash Position of approx.$50 Million Expected at Closing
-Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months
https://www.advaxis.com/news-releases/news-release-details/advaxis-and-biosight-announce-entry-definitive-merger-agreement
